{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:44:25Z","timestamp":1785300265385,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ashjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jash.2014.07.033","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T03:47:00Z","timestamp":1406864820000},"page":"709-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients"],"prefix":"10.1016","volume":"8","author":[{"given":"Anat","family":"Hass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Mashavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Shargorodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2014.07.033_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2265.2006.02474.x","article-title":"The endocrine function of adipose tissue: an update","volume":"64","author":"Ronti","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jash.2014.07.033_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2006.03.003","article-title":"Leptin and atherosclerosis","volume":"189","author":"Beltowski","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jash.2014.07.033_bib3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00109-002-0378-7","article-title":"Adiponectin: a link between excess adiposity and associated comorbidities?","volume":"80","author":"Ukkola","year":"2002","journal-title":"J Mol Med"},{"key":"10.1016\/j.jash.2014.07.033_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/ijo.2009.37","article-title":"Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis?","volume":"33","author":"Shargorodsky","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jash.2014.07.033_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1210\/jc.2003-031012","article-title":"Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation","volume":"89","author":"Tan","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2014.07.033_bib6","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.atherosclerosis.2006.11.044","article-title":"Low levels of adiponectin predict worsening of arterial morphology and function","volume":"194","author":"St\u00f6rk","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jash.2014.07.033_bib7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1096\/fasebj.13.10.1231","article-title":"Leptin induces oxidative stress in human endothelial cells","volume":"13","author":"Bouloumie","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.jash.2014.07.033_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.atherosclerosis.2010.10.047","article-title":"Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease. The Heart and Soul Study","volume":"217","author":"Ku","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jash.2014.07.033_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-958630","article-title":"Adiponectin and cardiovascular mortality: evidence for \u201creverse epidemiology\u201d","volume":"39","author":"Rathmann","year":"2007","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jash.2014.07.033_bib10","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.2337\/diacare.27.10.2488","article-title":"Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients","volume":"27","author":"Satoh","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.07.033_bib11","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1161\/STROKEAHA.107.485540","article-title":"Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery","volume":"38","author":"Norata","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.jash.2014.07.033_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","article-title":"Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy","volume":"43","author":"Goodfriend","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.07.033_bib13","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","article-title":"Human adipocytes secrete mineralocorticoid-releasing factors","volume":"100","author":"Ehrhart-Bornstein","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jash.2014.07.033_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tem.2008.01.004","article-title":"Adipose cell-adrenal interactions: current knowledge and future perspectives","volume":"19","author":"Ronconi","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jash.2014.07.033_bib15","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1210\/endo.132.6.8504747","article-title":"Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes","volume":"132","author":"Rondinone","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.jash.2014.07.033_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1751-7133.2011.00276.x","article-title":"Association of low plasma adiponectin with early diastolic dysfunction","volume":"18","author":"Negi","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.jash.2014.07.033_bib17","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1210\/en.2008-1018","article-title":"Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 Adipocytes","volume":"150","author":"Wada","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.jash.2014.07.033_bib18","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2014.07.033_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.atherosclerosis.2006.12.036","article-title":"High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering","volume":"197","author":"Shargorodsky","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jash.2014.07.033_bib20","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1161\/hc5001.101061","article-title":"Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS)","volume":"104","author":"Wallace","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2014.07.033_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jacc.2008.09.035","article-title":"Leptin and coronary heart disease: prospective study and systematic review","volume":"53","author":"Sattar","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2014.07.033_bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/oby.2007.191","article-title":"Tepel Low serum leptin predicts mortality in patients with chronic kidney disease stage 5","volume":"15","author":"Scholze","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jash.2014.07.033_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/1354750X.2012.730550","article-title":"Leptin to adiponectin ratio as a useful predictor for cardiac syndrome X","volume":"18","author":"Liao","year":"2013","journal-title":"Biomarkers"},{"key":"10.1016\/j.jash.2014.07.033_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2001-14951","article-title":"Effects of angiotensin 2 on adipose conversion and expressionof genes of the renin-angiotensinogen system in human preadipocytes","volume":"33","author":"Schiling","year":"2001","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jash.2014.07.033_bib25","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1210\/jc.2002-021836","article-title":"Angiotensin 2 recepror blocker valsartan suppresses reactive oxygen species generation in leucocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action","volume":"88","author":"Dandona","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2014.07.033_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1440-1681.1996.tb02784.x","article-title":"Remodelling of resistanse arteries in genetically hypertensive rates by treatment with valsartan, an angiotensin 2 receptor antagonist","volume":"23","author":"Lendingham","year":"1996","journal-title":"Clin Exper Pharmacol"},{"key":"10.1016\/j.jash.2014.07.033_bib27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjcard.2006.10.068","article-title":"Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials)","volume":"99","author":"Andraws","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2014.07.033_bib28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.jash.2014.07.033_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2710.2007.00820.x","article-title":"Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone","volume":"32","author":"Derosa","year":"2007","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jash.2014.07.033_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1291\/hypres.29.849","article-title":"Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha","volume":"29","author":"Derosa","year":"2006","journal-title":"Hypertens Res"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114006937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114006937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:21:55Z","timestamp":1717183315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171114006937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1933171114006937"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2014.07.033","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2014.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}